Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

23 June 2014 : Original article  

Incidence of malignant neoplasia after heart transplantation – a comparison between cyclosporine a and tacrolimus

Uwe FuchsABD, Sarah KleinBCD, Armin ZittermannBCDE, Stephan M. EnsmingerDE, Uwe SchulzADF, Jan F. GummertBD

DOI: 10.12659/AOT.890199

Ann Transplant 2014; 19:300-304

Abstract

BACKGROUND: Heart transplant recipients are at increased risk of developing malignant neoplasms. Administration of the calcineurin inhibitors cyclosporine A (CSA) or tacrolimus (TAC) may contribute to this risk.

MATERIAL AND METHODS: We compared tumor incidence in heart transplant recipients receiving either CSA (n=25) or TAC (n=120) as maintenance immunosuppressive therapy. Exclusion criteria were therapy with mammalian target of rapamycin-inhibitors, death within the first postoperative year, re-transplantation, and age less than 18 years.

RESULTS: The 2 study groups were comparable with respect to sex, primary and concomitant diagnoses, and mean follow-up (60.7±19.3 months in the CSA group vs. 59.8±18.1 months in the TAC group; P=0.81). The CSA group was, however, significantly older compared with the TAC group (58.8±11.4 years vs. 49.1±13.0 years, P=0.001), as was the donor age of the CSA group (43.2±11.2 years vs. 37.0±11.7 years, P=0.02). In the CSA group, 5 patients (20%) developed malignant neoplasms compared with 10 patients (8.3%) in the TAC group (P=0.14). Covariate-adjusted 5-year tumor-free survival was comparable between groups (relative risk for the CSA group =1.162 [95% CI: 0.378–3.572; P=0.794]). Moreover, covariate-adjusted 5-year overall survival did not differ between the 2 groups (relative risk for the CSA group =1.95 [95% CI: 0.53–7.19; P=0.36). The incidence of infection, acute rejection, graft vasculopathy, renal failure, and neurological complications was also comparable between the 2 groups.

CONCLUSIONS: Our data indicate that tumor incidence does not significantly differ in patients receiving CSA or TAC as maintenance therapy.

Keywords: Neoplasms, Second Primary, Tacrolimus, Cyclosporine A, Immunosuppression, calcineurin-inhibitors, Heart Transplantation

Add Comment 0 Comments

In Press

Original article  

Post-Donation Regret and Anxiety Among Family Living Liver Donors: The Mediating Roles of Family Relationsh...

Ann Transplant In Press; DOI: 10.12659/AOT.944176  

Original article  

Effect of the Organ Donation Quality System on Donation Activity of Warsaw Hospitals

Ann Transplant In Press; DOI: 10.12659/AOT.943520  

Original article  

Clonal Hematopoiesis-Associated Gene Mutations Affect Acute Graft-Versus-Host Disease After Hematopoietic S...

Ann Transplant In Press; DOI: 10.12659/AOT.943688  

Original article  

Impact of Recipient and Donor Body Mass Index on Survival Outcomes After Intestinal Transplantation: A Unit...

Ann Transplant In Press; DOI: 10.12659/AOT.943994  

Most Viewed Current Articles

05 Apr 2022 : Original article   12,201

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

22 Nov 2022 : Original article   8,720

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

12 Jan 2022 : Original article   8,640

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

15 Mar 2022 : Case report   6,496

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358